VIKING THERAPEUTICS INC (VKTX) Stock Fundamental Analysis
NASDAQ:VKTX - Nasdaq - US92686J1060 - Common Stock - Currency: USD
We assign a fundamental rating of 3 out of 10 to VKTX. VKTX was compared to 549 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VKTX as it has an excellent financial health rating, but there are worries on the profitability. VKTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
VKTX had negative earnings in the past year.
In the past year VKTX has reported a negative cash flow from operations.
VKTX had negative earnings in each of the past 5 years.
VKTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VKTX has a Return On Assets of -20.72%. This is in the better half of the industry: VKTX outperforms 77.41% of its industry peers.
The Return On Equity of VKTX (-21.57%) is better than 84.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.72% | ||
| ROE | -21.57% | ||
| ROIC | N/A |
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VKTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, VKTX has more shares outstanding
VKTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 86.96 indicates that VKTX is not in any danger for bankruptcy at the moment.
The Altman-Z score of VKTX (86.96) is better than 99.27% of its industry peers.
There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 86.96 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
VKTX has a Current Ratio of 25.86. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of VKTX (25.86) is better than 96.72% of its industry peers.
VKTX has a Quick Ratio of 25.86. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 25.86, VKTX belongs to the top of the industry, outperforming 96.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 25.86 | ||
| Quick Ratio | 25.86 |
3. Growth
3.1 Past
The earnings per share for VKTX have decreased strongly by -62.77% in the last year.
EPS 1Y (TTM)-62.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
VKTX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.59% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-92.69%
EPS Next 2Y-61.84%
EPS Next 3Y-44.88%
EPS Next 5Y4.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VKTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as VKTX's earnings are expected to decrease with -44.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.84%
EPS Next 3Y-44.88%
5. Dividend
5.1 Amount
No dividends for VKTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:VKTX (8/19/2025, 10:12:10 AM)
25.965
-16.13 (-38.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners69.64%
Inst Owner Change-2.62%
Ins Owners2.15%
Ins Owner Change0.51%
Market Cap2.92B
Analysts84.8
Price Target92.94 (257.94%)
Short Float %26.2%
Short Ratio6.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.64%
Min EPS beat(2)-27.37%
Max EPS beat(2)-23.91%
EPS beat(4)1
Avg EPS beat(4)-12.66%
Min EPS beat(4)-27.37%
Max EPS beat(4)14.36%
EPS beat(8)4
Avg EPS beat(8)-1.83%
EPS beat(12)6
Avg EPS beat(12)-1.06%
EPS beat(16)8
Avg EPS beat(16)0.69%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.45%
PT rev (3m)-0.39%
EPS NQ rev (1m)-39.48%
EPS NQ rev (3m)-63.22%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.67 | ||
| P/tB | 3.67 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.53
EYN/A
EPS(NY)-2.62
Fwd EYN/A
FCF(TTM)-1.36
FCFYN/A
OCF(TTM)-1.36
OCFYN/A
SpS0
BVpS7.07
TBVpS7.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.72% | ||
| ROE | -21.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-25.43%
ROA(5y)-23.56%
ROE(3y)-28.18%
ROE(5y)-25.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 25.86 | ||
| Quick Ratio | 25.86 | ||
| Altman-Z | 86.96 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-62.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-190%
EPS Next Y-92.69%
EPS Next 2Y-61.84%
EPS Next 3Y-44.88%
EPS Next 5Y4.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-70.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-106.14%
EBIT Next 3Y-47%
EBIT Next 5Y-26.07%
FCF growth 1Y-152.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-152.08%
OCF growth 3YN/A
OCF growth 5YN/A